Cargando…

Peptides Targeting Fms-Related Tyrosine Kinase-4 Activate the Function of Natural Killer Cells in Acute Myeloid Leukemia

BACKGROUND AND OBJECTIVES: The increased expression for the Fms-related tyrosine kinase-4 (FLT-4, known as VEGFR-3) is relevant to dysfunctional natural killer (NK) cells in acute myeloid leukemia (AML). MAZ51 (M), a VEGFR-3 inhibiting chemical, was effectively restored the function of NK cells via...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Soojin, Kim, Hee-Je, Hwang, Hee-Sun, Han, A-Reum
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for Stem Cell Research 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611315/ https://www.ncbi.nlm.nih.gov/pubmed/34158419 http://dx.doi.org/10.15283/ijsc21083

Ejemplares similares

Detection of nucleophosmin and FMS-like tyrosine kinase-3 gene mutations in acute myeloid leukemia
por: Pazhakh, Vahid, et al.
Publicado: (2011)

Sorafenib-induced Thyroiditis in FMS-like Tyrosine Kinase 3-internal Tandem Duplication-mutated Acute Myeloid Leukemia
por: Sun, Jie, et al.
Publicado: (2016)

FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile
por: Garciaz, Sylvain, et al.
Publicado: (2023)

Fms-like tyrosine kinase 3-internal tandem duplications epigenetically activates checkpoint kinase 1 in acute myeloid leukemia cells
por: Zhang, Yudong, et al.
Publicado: (2021)

Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia
por: Katayama, Kazuhiro, et al.
Publicado: (2018)

How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?
por: Perrone, Salvatore, et al.
Publicado: (2023)

Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms
por: Ruvolo, Peter P., et al.
Publicado: (2017)

The Endothelial Glycocalyx as a Target of Excess Soluble Fms-like Tyrosine Kinase-1
por: Schulz, Annika, et al.
Publicado: (2023)

Serum soluble FMS-like tyrosine kinase-1 in ectopic pregnancy
por: Selvarajan, Sathya, et al.
Publicado: (2019)

Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model
por: Tsuzuki, Hirofumi, et al.
Publicado: (2022)

Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
por: Fernandez, Solène, et al.
Publicado: (2019)

Soluble fms-Like Tyrosine Kinase 1 Localization in Renal Biopsies of CKD
por: Zsengellér, Zsuzsanna K., et al.
Publicado: (2019)

Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia
por: Ciaffaglione, Valeria, et al.
Publicado: (2022)

Clinical Benefits and Safety of FMS-Like Tyrosine Kinase 3 Inhibitors in Various Treatment Stages of Acute Myeloid Leukemia: A Systematic Review, Meta-Analysis, and Network Meta-Analysis
por: Xu, Qingyu, et al.
Publicado: (2021)

Regulation of expression level of fms-like tyrosine kinase-4 is related to osteoclast differentiation
por: Zhu, Yi, et al.
Publicado: (2015)

Fms-like tyrosine kinase 3 is a regulator of the cardiac side population in mice
por: Della Verde, Giacomo, et al.
Publicado: (2021)

Soluble FMS-Like Tyrosine Kinase-1: Role in placenta accreta spectrum disorder
por: Lumbanraja, Sarma, et al.
Publicado: (2022)

Natural killer cell-based immunotherapy for acute myeloid leukemia
por: Xu, Jing, et al.
Publicado: (2020)

FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics
por: Rezaei, Narges, et al.
Publicado: (2017)

Clinical implications of combination therapy with quizartinib and craniospinal irradiation for refractory acute myeloid leukemia positive for FMS‐like tyrosine kinase 3‐internal tandem duplication with central nervous system involvement
por: Suga, Makiko, et al.
Publicado: (2022)

Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia
por: Katagiri, Seiichiro, et al.
Publicado: (2022)

2-Methoxyestradiol combined with ascorbic acid facilitates the apoptosis of chronic myeloid leukemia cells via the microRNA-223/Fms-like tyrosine kinase 3/phosphatidylinositol-3 kinase/protein kinase B axis
por: Zhang, Suwei, et al.
Publicado: (2022)

Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia
por: Kim, Shin-Young, et al.
Publicado: (2008)

FMS-like tyrosine kinase 3 is required for dendritic cell development in peripheral lymphoid tissues
por: Waskow, Claudia, et al.
Publicado: (2008)

Fms-Like Tyrosine Kinase 3 Ligand Controls Formation of Regulatory T Cells in Autoimmune Arthritis
por: Svensson, Mattias N. D., et al.
Publicado: (2013)

Soluble Fms-Like Tyrosine Kinase-1 Alters Cellular Metabolism and Mitochondrial Bioenergetics in Preeclampsia
por: Sánchez-Aranguren, Lissette C., et al.
Publicado: (2018)

Soluble Fms-Like Tyrosine Kinase-1 Is A Marker of Endothelial Dysfunction During Sepsis
por: Greco, Marilena, et al.
Publicado: (2018)

FMS‐like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer
por: Hasegawa, Hiroko, et al.
Publicado: (2020)

FMS-Related Tyrosine Kinase 3 Ligand Promotes Radioresistance in Esophageal Squamous Cell Carcinoma
por: Zhu, Zuoquan, et al.
Publicado: (2021)

In-Silico Screening of Novel Synthesized Thienopyrimidines Targeting Fms Related Receptor Tyrosine Kinase-3 and Their In-Vitro Biological Evaluation
por: Elmongy, Elshaymaa I., et al.
Publicado: (2022)

Natural Killer Cell Activity Test Helps to Suspect Aggressive Natural Killer Cell Leukemia - Diagnostic Challenge
por: You, Eunkyoung, et al.
Publicado: (2023)

The role of natural killer cells in chronic myeloid leukemia
por: Danier, Anna Carolyna Araújo, et al.
Publicado: (2011)

Hyperthyroidism with concurrent FMS-like tyrosine kinase 3-internal tandem duplication-positive acute promyelocytic leukemia: A case report and review of the literature
por: JIANG, YAJIAN, et al.
Publicado: (2014)

Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity
por: Yi, Hai, et al.
Publicado: (2016)

Serum Soluble Fms-Like Tyrosine Kinase 1 (sFlt-1) Predicts the Severity of Acute Pancreatitis
por: Dumnicka, Paulina, et al.
Publicado: (2016)

Clinical Impact of Percentage of Natural Killer Cells and Natural Killer-Like T Cell Population in Acute Myeloid Leukemia
por: Jamal, Esraa, et al.
Publicado: (2020)

Effect of High VEGF-C mRNA Expression on Achievement of Complete Remission in Adult Acute Myeloid Leukemia
por: Lee, Sung-Eun, et al.
Publicado: (2018)

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
por: Kentsis, Alex, et al.
Publicado: (2012)

PB1834: CLEVO: A NON-INTERVENTIONAL STUDY TO INVESTIGATE CLONAL EVOLUTION OF FMS-LIKE TYROSINE KINASE 3 (FLT3) GENE MUTATIONS DURING DISEASE PROGRESSION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Vyas, P., et al.
Publicado: (2022)

Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets
por: Kasi, Pashtoon M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3dli9rnp88g3k6lp46oljnav6v